George Robert J, Sturmoski Mark A, Anant Shrikant, Houchen Courtney W
Washington University School of Medicine, Department of Internal Medicine, St. Louis, Missouri 63110, USA.
Prostaglandins Other Lipid Mediat. 2007 Feb;83(1-2):112-20. doi: 10.1016/j.prostaglandins.2006.10.005. Epub 2007 Jan 3.
The anti-apoptotic effect of PGE(2) was examined in Jurkat cells (human T-cell leukemia) by incubation with PGE(2) (5 nM) prior to treatment with the cancer chemotherapeutic agent camptothecin. Apoptosis was evaluated by caspase-3 activity in cell extracts and flow cytometry of propidium iodide-labeled cells. Pre-incubation with PGE(2) reduced camptothecin-induced caspase activity by 30% and apoptosis by 35%, respectively. Pharmacological data demonstrate that the EP4 receptor is responsible for mediating the protection from camptothecin-induced apoptosis. Pre-treatment of the cells with the EP4 antagonist (EP4A) prior to PGE(2) and camptothecin abolished the increased survival effect of PGE(2). Specific inhibition of the downstream of PI3 kinase or AKT/protein kinase but not protein kinase A prevents the observed increase in cell survival elicited by PGE(2). These findings have critical implications regarding the mechanism and potential application of PGE(2) receptor specific inhibition in cancer therapy.
在人T细胞白血病Jurkat细胞中,通过在癌症化疗药物喜树碱处理前用PGE(2)(5 nM)孵育来检测PGE(2)的抗凋亡作用。通过细胞提取物中的caspase-3活性以及碘化丙啶标记细胞的流式细胞术评估细胞凋亡。与PGE(2)预孵育分别使喜树碱诱导的caspase活性降低30%,细胞凋亡降低35%。药理学数据表明,EP4受体负责介导对喜树碱诱导凋亡的保护作用。在PGE(2)和喜树碱之前用EP4拮抗剂(EP4A)预处理细胞消除了PGE(2)增加的存活效应。PI3激酶或AKT/蛋白激酶下游的特异性抑制而非蛋白激酶A可阻止观察到的由PGE(2)引起的细胞存活增加。这些发现对于PGE(2)受体特异性抑制在癌症治疗中的机制和潜在应用具有关键意义。